| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
|
Medicine details |
|
| Medicine name | pembrolizumab (Keytruda®) |
| Formulation | 50 mg powder for concentrate for solution for infusion |
| Reference number | 2802 |
| Indication | Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 09/07/2015 |
| NICE guidance | TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |